212 related articles for article (PubMed ID: 19768354)
1. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
Garcia-Rodriguez JC; Sosa-Teste I
ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the delivery of erythropoietin and its variants into the ischemic brain.
Hermann DM
ScientificWorldJournal; 2009 Sep; 9():967-9. PubMed ID: 19768353
[TBL] [Abstract][Full Text] [Related]
3. Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro-EPO for ischemic insults to the gerbil brain.
Gao Y; Mengana Y; Cruz YR; Muñoz A; Testé IS; García JD; Wu Y; Rodríguez JC; Zhang C
J Histochem Cytochem; 2011 Feb; 59(2):214-27. PubMed ID: 21339183
[TBL] [Abstract][Full Text] [Related]
4. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment.
Parra AL; Rodriguez JC
Cent Nerv Syst Agents Med Chem; 2012 Mar; 12(1):60-8. PubMed ID: 22376076
[TBL] [Abstract][Full Text] [Related]
5. Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia.
Rodríguez Cruz Y; Mengana Támos Y; Muñoz Cernuda A; Subirós Martines N; González-Quevedo A; Sosa Testé I; García Rodríguez JC
ScientificWorldJournal; 2010 Nov; 10():2288-300. PubMed ID: 21103798
[TBL] [Abstract][Full Text] [Related]
6. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC
J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967
[TBL] [Abstract][Full Text] [Related]
7. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
Merelli A; Caltana L; Lazarowski A; Brusco A
Drug Metabol Drug Interact; 2011; 26(2):65-9. PubMed ID: 21756166
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.
Merelli A; Czornyj L; Lazarowski A
Int J Neurosci; 2015; 125(11):793-7. PubMed ID: 25405533
[TBL] [Abstract][Full Text] [Related]
9. Nonhematopoietic variants of erythropoietin in ischemic stroke: need for step-wise proof-of-concept studies.
Hermann DM
ScientificWorldJournal; 2010 Nov; 10():2285-7. PubMed ID: 21103797
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.
Sirén AL; Fasshauer T; Bartels C; Ehrenreich H
Neurotherapeutics; 2009 Jan; 6(1):108-27. PubMed ID: 19110203
[TBL] [Abstract][Full Text] [Related]
11. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
Hanson LR; Frey WH
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
[TBL] [Abstract][Full Text] [Related]
12. Dose effect evaluation and therapeutic window of the neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil.
Teste IS; Tamos YM; Cruz YR; Cernada AM; Rodríguez JC; Martínez NS; Antich RM; González-Quevedo A; Rodríguez JC
ScientificWorldJournal; 2012; 2012():607498. PubMed ID: 22701364
[TBL] [Abstract][Full Text] [Related]
13. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.
Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C
Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120
[TBL] [Abstract][Full Text] [Related]
14. Intranasal erythropoietin therapy in nervous system disorders.
Genc S; Zadeoglulari Z; Oner MG; Genc K; Digicaylioglu M
Expert Opin Drug Deliv; 2011 Jan; 8(1):19-32. PubMed ID: 21143002
[TBL] [Abstract][Full Text] [Related]
15. A neuroprotective derivative of erythropoietin that is not erythropoietic.
Doggrell SA
Expert Opin Investig Drugs; 2004 Nov; 13(11):1517-9. PubMed ID: 15500399
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia.
Liu W; Shen Y; Plane JM; Pleasure DE; Deng W
Exp Neurol; 2011 Aug; 230(2):227-39. PubMed ID: 21596035
[TBL] [Abstract][Full Text] [Related]
17. Intranasal erythropoietin ameliorates neurological function impairments and neural pathology in mice with chronic alcoholism by regulating autophagy‑related Nrf2 degradation.
Nie X; Wang W; Wang Q; Zhu D; Song H
Mol Med Rep; 2019 Feb; 19(2):1139-1149. PubMed ID: 30535439
[TBL] [Abstract][Full Text] [Related]
18. Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
Thériault P; Le Béhot A; ElAli A; Rivest S
Oncotarget; 2016 Jun; 7(24):35552-35561. PubMed ID: 27248662
[TBL] [Abstract][Full Text] [Related]
19. Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hypoxia model induced by CoCl2 in rats.
Merelli A; Caltana L; Girimonti P; Ramos AJ; Lazarowski A; Brusco A
Neurotox Res; 2011 Aug; 20(2):182-92. PubMed ID: 21116766
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin in stroke: quo vadis.
Digicaylioglu M
Expert Opin Biol Ther; 2010 Jun; 10(6):937-49. PubMed ID: 20394473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
